BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity

We examined the impact of pre-existing SARS-CoV-2-specific cellular immunity on BNT162b2 mRNA COVID-19 vaccine reactogenicity. Of 96 healthcare workers (HCWs), 76% reported any vaccine reaction (first dose: 70%, second dose: 67%), none of which was severe. Following first dose, systemic reactions we...

Descripción completa

Detalles Bibliográficos
Autores principales: Vizcarra, Pilar, Haemmerle, Johannes, Velasco, Hector, Velasco, Tamara, Fernández-Escribano, Marina, Vallejo, Alejandro, Casado, José L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580836/
https://www.ncbi.nlm.nih.gov/pubmed/34802792
http://dx.doi.org/10.1016/j.vaccine.2021.10.074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580836/
https://www.ncbi.nlm.nih.gov/pubmed/34802792
http://dx.doi.org/10.1016/j.vaccine.2021.10.074

Ejemplares similares